Eflornithine functions as an irreversible inhibitor of ornithine decarboxylase for excessive hair. Reducing enzymatic activity within follicles, the compound effectively slows the cycle of hair production.
Eflornithine belongs to a class of compounds known as ornithine decarboxylase inhibitors. Its primary therapeutic role is to slow the production of certain proteins that contribute to skin cell growth. This mechanism allows the substance to be used in products that aim to reduce unwanted facial hair growth. In Singapore, the ingredient appears in formulations such as Vaniqa and other eflornithine-based preparations.
Several topical preparations feature eflornithine as the key component. The most widely recognized brand in the region is Vaniqa, marketed as a cream for facial hair management. Generic versions may list the ingredient simply as “eflornithine” on the label. Formulations are typically supplied as creams or gels, designed for daily application to the targeted skin area. While the active compound is the same, individual products can differ in concentration and packaging.
These applications reflect typical patient groups who seek a non-invasive approach to hair-related concerns.
The substance interferes with an enzyme that assists cells in producing polyamines, molecules needed for hair-follicle activity. By limiting this enzyme’s action, the growth cycle of hair is lengthened, resulting in finer and slower-growing strands. The effect is localized to the area where the cream is applied, with minimal systemic absorption reported in clinical observations.
These reactions are generally short-lived and resolve without intervention.
If any of these signs appear, discontinuation of the product is advisable and professional guidance should be sought.
For a complete list of possible interactions, refer to the specific medication’s detailed information.
The cream should be stored in a cool, dry place away from direct sunlight to maintain potency. Most eflornithine medications are intended for continuous use rather than a short-term course, allowing gradual changes to become visible over several weeks. Product instructions often advise applying a thin layer to clean, dry skin twice daily. For detailed usage, dosing, and administration, refer to the specific medication’s clinical information.
This article provides an educational overview of eflornithine as an active substance and does not constitute medical advice. Individual eflornithine medications, such as Vaniqa, may vary in formulation, strength, and usage directions. The information presented carries no liability for clinical decisions. Readers are encouraged to review the labeling of their specific product and seek guidance from a qualified healthcare professional when appropriate.
